Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET
Company Participants
Dawn Schottlandt - Managing Director-Argot Partners
Joe Ciaffoni - Chief Executive Officer
Colleen Tupper - Chief Financial Officer
Scott Dreyer - Chief Commercial Officer
Conference Call Participants
David Amsellem - Piper Sandler
Tim Lugo - William Blair
Brandon Folkes - Cantor Fitzgerald
Serge Belanger - Needham & Company
Greg Fraser - Truist Securities
Oren Livnat - H.C. Wainwright
Operator
Greetings, and welcome to the Collegium Pharmaceutical Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation.
[Operator Instructions] Please note, that this conference is being recorded. I will now turn the call over to Dawn Schottlandt, at Argot Partners. Thank you. You may begin.
Dawn Schottlandt
Welcome to Collegium Pharmaceutical's Third Quarter 2022 Earnings Conference Call. I am joined today by Joe Ciaffoni Collegium's, Chief Executive Officer; Colleen Tupper, Chief Financial Officer and Scott Dreyer, Chief Commercial Officer.
Before we begin today's call, I want to remind participants that none of the information presented today is intended to be promotional and that any forward-looking statements made today are pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995.
You are cautioned that such forward-looking statements involve risks and uncertainties, including and without limitation, the risks that we may not be able to derive the expected benefits of the acquisition of BioDelivery Sciences International on the proposed schedule or at all, [Technical Difficulty] also reducing fully commercialize [ph] our products and that we may incur significant expenses and may not prevail in the current or future litigation pertaining to our business.
These risks and other risks of the company are detailed in the company's periodic reports filed with the Securities and Exchange Commission. Our future results may differ materially from our current expectations discussed today.
Our earnings press release and this call will include discussion of certain non-GAAP information. You can find our earnings press release, including relevant non-GAAP reconciliations on our corporate website at collegiumpharma.com.
I will now turn the call over to Collegium's CEO, Joe Ciaffoni.
Joe Ciaffoni
Thank you, Dawn. Good afternoon, and thank you, everyone, for joining the call. Today, we will discuss our performance during the third quarter and through the first nine months of the year and provide perspective on our outlook for the remainder of 2024 and what we expect 2023 to be advanced [Technical Difficulty].